PURPOSE: Alpha-methyl CoA racemase (AMACR) is used as an immunohistochemical marker for renal cell carcinoma (RCC) subtyping to distinguish papillary (pap) RCC. Expression of AMACR in other renal tumor subtypes is inhomogeneous, and the clinical and prognostic value of AMACR is unknown. The aim of this study was to asses AMACR protein expression in different RCC subtypes and to investigate its prognostic significance. METHODS: Protein expression of AMACR was analyzed in 1,088 renal tumor samples, among them 809 clear cell RCC and 151 papRCC, by immunohistochemistry using tissue microarry (TMA) technique. Results were correlated with clinicopathological data and to follow-up data [overall (OS)/cancer-specific survival (CSS)]. RESULTS: Frequency of AMACR expression was significantly higher in papRCC compared to other tumor subtypes (83% vs. 15-35%, p < 0.0001). Presence of AMACR did not correlate with stage or nodal metastases in papRCC. In a dichotomized scoring (negative vs. positive expression), an inverse correlation between higher grade (p = 0.03) and presence of distant metastasis (p = 0.014) was observed in papRCC. AMACR expression correlated with the presence of nodal metastasis in ccRCC (p = 0.02). Both in ccRCC and in papRCC, OS and CSS did not correlate with the AMACR expression status. CONCLUSIONS: The high expression in papRCC confirms AMACR to be a marker for subtype differentiation in RCC, while a missing expression in this subtype seems to be associated with negative pathological features. However, in contrast to other tumor entities, AMACR expression seems to have a limited prognostic impact in renal carcinoma, especially with regard to survival.
PURPOSE: Alpha-methyl CoA racemase (AMACR) is used as an immunohistochemical marker for renal cell carcinoma (RCC) subtyping to distinguish papillary (pap) RCC. Expression of AMACR in other renal tumor subtypes is inhomogeneous, and the clinical and prognostic value of AMACR is unknown. The aim of this study was to asses AMACR protein expression in different RCC subtypes and to investigate its prognostic significance. METHODS: Protein expression of AMACR was analyzed in 1,088 renal tumor samples, among them 809 clear cell RCC and 151 papRCC, by immunohistochemistry using tissue microarry (TMA) technique. Results were correlated with clinicopathological data and to follow-up data [overall (OS)/cancer-specific survival (CSS)]. RESULTS: Frequency of AMACR expression was significantly higher in papRCC compared to other tumor subtypes (83% vs. 15-35%, p < 0.0001). Presence of AMACR did not correlate with stage or nodal metastases in papRCC. In a dichotomized scoring (negative vs. positive expression), an inverse correlation between higher grade (p = 0.03) and presence of distant metastasis (p = 0.014) was observed in papRCC. AMACR expression correlated with the presence of nodal metastasis in ccRCC (p = 0.02). Both in ccRCC and in papRCC, OS and CSS did not correlate with the AMACR expression status. CONCLUSIONS: The high expression in papRCC confirms AMACR to be a marker for subtype differentiation in RCC, while a missing expression in this subtype seems to be associated with negative pathological features. However, in contrast to other tumor entities, AMACR expression seems to have a limited prognostic impact in renal carcinoma, especially with regard to survival.
Authors: Vincent Molinié; André Balaton; Samuel Rotman; Douha Mansouri; Isabelle De Pinieux; Toufik Homsi; Louis Guillou Journal: Hum Pathol Date: 2006-06 Impact factor: 3.466
Authors: Börje Ljungberg; Damian C Hanbury; Marcus A Kuczyk; Axel S Merseburger; Peter F A Mulders; Jean-Jacques Patard; Ioanel C Sinescu Journal: Eur Urol Date: 2007-03-28 Impact factor: 20.096
Authors: H Moch; P Schraml; L Bubendorf; M Mirlacher; J Kononen; T Gasser; M J Mihatsch; O P Kallioniemi; G Sauter Journal: Am J Pathol Date: 1999-04 Impact factor: 4.307
Authors: Mark A Rubin; Tarek A Bismar; Ove Andrén; Lorelei Mucci; Robert Kim; Ronglai Shen; Debashis Ghosh; John T Wei; Arul M Chinnaiyan; Hans-Olov Adami; Philip W Kantoff; Jan-Erik Johansson Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-06 Impact factor: 4.254
Authors: Alexander S Parker; Christine M Lohse; John C Cheville; David D Thiel; Bradley C Leibovich; Michael L Blute Journal: Urology Date: 2006-10 Impact factor: 2.649
Authors: Zhong Jiang; Gary R Fanger; Bruce A Woda; Barbara F Banner; Paul Algate; Karen Dresser; Jiangchun Xu; Peiguo G Chu Journal: Hum Pathol Date: 2003-08 Impact factor: 3.466
Authors: Anne Lin; Martin R Weiser; David S Klimstra; Philip B Paty; Laura H Tang; Hikmat Al-Ahmadie; Sun Hoo Park; Jose G Guillem; Larissa Temple; W Douglas Wong; William L Gerald; Jinru Shia Journal: Hum Pathol Date: 2007-04-18 Impact factor: 3.466
Authors: Rainer Kuefer; Sooryanarayana Varambally; Ming Zhou; Peter C Lucas; Martin Loeffler; Hubertus Wolter; Torsten Mattfeldt; Richard E Hautmann; Juergen E Gschwend; Terrence R Barrette; Rodney L Dunn; Arul M Chinnaiyan; Mark A Rubin Journal: Am J Pathol Date: 2002-09 Impact factor: 4.307
Authors: Zhong Jiang; Chin-Lee Wu; Bruce A Woda; Karen Dresser; Jiangchun Xu; Gary R Fanger; Ximing J Yang Journal: Am J Surg Pathol Date: 2002-09 Impact factor: 6.394
Authors: Oluwole Fadare; Vinita Parkash; Katja Gwin; Krisztina Z Hanley; Elke A Jarboe; Sharon X Liang; Charles M Quick; Wenxin Zheng; Kojo R Rawish; Jonathan L Hecht; Mohamed M Desouki Journal: Hum Pathol Date: 2013-10-10 Impact factor: 3.466
Authors: Matthias May; Atiqullah Aziz; Richard Zigeuner; Thomas Chromecki; Luca Cindolo; Luigi Schips; Ottavio De Cobelli; Bernardo Rocco; Cosimo De Nunzio; Andrea Tubaro; Ioman Coman; Michael Truss; Orietta Dalpiaz; Bernd Hoschke; Christian Gilfrich; Bogdan Feciche; Anette Stoltze; Fabian Fenske; Hans-Martin Fritsche; Robert S Figenshau; Kerry Madison; Manuel Sánchez-Chapado; Maria Del Carmen Santiago Martin; Luigi Salzano; Giuseppe Lotrecchiano; Steven Joniau; Raphaela Waidelich; Christian Stief; Sabine Brookman-May Journal: World J Urol Date: 2013-04-09 Impact factor: 4.226
Authors: Till Eichenauer; Navid Shadanpour; Martina Kluth; Cosima Göbel; Sören Weidemann; Christoph Fraune; Franziska Büscheck; Claudia Hube-Magg; Christina Möller-Koop; Roland Dahlem; Margit Fisch; Michael Rink; Silke Riechardt; Eike Burandt; Christian Bernreuther; Sarah Minner; Ronald Simon; Guido Sauter; Waldemar Wilczak; Till Clauditz Journal: World J Surg Oncol Date: 2020-06-13 Impact factor: 2.754
Authors: Till Eichenauer; Luca Simmendinger; Christoph Fraune; Tim Mandelkow; Niclas C Blessin; Martina Kluth; Claudia Hube-Magg; Katharina Möller; Till Clauditz; Sören Weidemann; Roland Dahlem; Margit Fisch; Silke Riechardt; Ronald Simon; Guido Sauter; Franziska Büscheck; Michael Rink Journal: World J Urol Date: 2020-04-17 Impact factor: 4.226